Charles Medawar
- Economics and Econometrics top 10%
- Strategy and Management top 10%
- Pharmacology top 10%
- Toxicology top 5%
- Pharmacology
- Topics
- Pharmaceutical industry and healthcare (3 papers)Pharmaceutical Economics and Policy (3 papers)Pharmaceutical Practices and Patient Outcomes (3 papers)
- Partner nations
- United Kingdom
In The Last Decade
Charles Medawar
18 papers receiving 351 citations
Peers
Comparison fields: 5 of 84
- Economics and Econometrics 85
- Strategy and Management 78
- Pharmacology 78
- Toxicology 71
- Pharmacology 64
Countries citing papers authored by Charles Medawar
This map shows the geographic impact of Charles Medawar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Medawar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Medawar more than expected).
Fields of papers citing papers by Charles Medawar
This network shows the impact of papers produced by Charles Medawar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Medawar. The network helps show where Charles Medawar may publish in the future.
Co-authorship network of co-authors of Charles Medawar
This figure shows the co-authorship network connecting the top 25 collaborators of Charles Medawar. A scholar is included among the top collaborators of Charles Medawar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Medawar. Charles Medawar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine | 57 |
| 2 | Medicines out of Control? Antidepressants and the Conspiracy of Goodwill | 38 |
| 3 | Medicines Out Of Control | 4 |
| 4 | 56 | |
| 5 | 2 | |
| 6 | 54 | |
| 7 | 5 | |
| 8 | 5 | |
| 9 | 10 | |
| 10 | Power and dependence: Social audit on the safety of medicines | 19 |
| 11 | 6 | |
| 12 | 1 | |
| 13 | International regulation of the supply and use of pharmaceuticals. | 5 |
| 14 | 1 | |
| 15 | Insult or injury?: An enquiry into the marketing and advertising of British food and drug products in the Third World | 19 |
| 16 | 16 | |
| 17 | The Social Audit Consumer Handbook: A Guide to the Social Responsibilities of Business to the Consumer | 4 |
| 18 | 115 | |
| 19 | 1 |
About Charles Medawar
Charles Medawar is a scholar working on Medical Terminology, Geriatrics and Gerontology and Toxicology, having authored 19 papers that have together received 418 indexed citations. Recurring topics across this work include Pharmaceutical industry and healthcare (3 papers), Pharmaceutical Economics and Policy (3 papers) and Pharmaceutical Practices and Patient Outcomes (3 papers). The work is most often cited by research in Toxicology (71 citations), Pharmacology (78 citations) and Medical Terminology (2 citations). Charles Medawar has collaborated with scholars based in United Kingdom. Frequent co-authors include Andrew Herxheimer, Anita Hardon, Andrew M. Bell, Elaine Rassaby and Brian Güthrie. Their work appears in journals such as Nature, The Lancet and Accounting Organizations and Society.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.